SN132D

DRUG2 trials

Sponsors

Spago Nanomedical AB

Conditions

Breast CancerEndometriosisPancreas Cancer

Phase 1

A First-in-human Clinical Evaluation of SN132D in Patients With Breast and Pancreatic Cancer

CompletedNCT04080024

Spago Nanomedical ABBreast Cancer, Pancreas Cancer

Start: 2019-08-23End: 2022-11-30Updated: 2022-12-09

Phase 2

Efficacy of SN132D in Patients With Suspected Endometriosis

CompletedNCT05664828

Spago Nanomedical ABEndometriosis

Start: 2022-11-17End: 2023-09-12Updated: 2023-12-12